A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8191-8197

  Canter, Robert J ^a   Qin, Li Xuan ^a   Maki, Robert G ^a   Brennan, Murray F ^a   Ladanyi, Marc ^a   Singer, Samuel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; ALKYLATING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYNOVIAL SARCOMA; TUMOR VOLUME; CONNECTIVE TISSUE TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; SARCOMA, SYNOVIAL;

EID: 58149356249     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0843     Document Type: Article

References (26)

1. Brennan MF, Singer S, Maki RG, O'Sullivan B. Sarcomas of the soft tissues and bone. In: DeVitaV, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1581 -637.
2. Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000;1:75-85.
3. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994;73:2506-11.
4. Kampe CE, Rosen G, Eilber F, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer 1993;72:2161 -9.
5. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. AnnSurg2007;246:105-13.
6. Okcu MF, Munsell M,Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003;21:1602-11.
7. Spillane AJ, A'Hern R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging,and prognosticassessment. J Clin Oncol 2000;18:3794-803.
8. Deshmukh R, Mankin HJ, Singer S. Synovial sarcoma: the importance of size and location for survival. Clin OrthopRelatRes2004;419:155-61.
9. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004;101: 627-34.
10. Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in112 patients with primary localized tumors of theextremity. J Clin Oncol 2000;18:2087-94.
11. Singer S, Baldini EH, Demetri GD, et al. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996;14:1201 -8.
12. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002;62:135-40.
13. Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of128 adult patients. J Clin Oncol 2001;19:525-34.
14. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338:153-60.
15. 15. Fletcher CD. Theevolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006;48:3-12.
16. Pisters PW, Harrison LB, Leung DH, et al. Long-termresults of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-68.
17. Antonescu CR, Kawai A, Leung DH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 2000;9:1 -8.
18. Jin Z, Lin DY, Wei LJ, et al. Rank-based inference for the accelerated failure time model. Biometrika 2003;90:341 -53.
19. Kalbfleisch JG, Prentice R. The statistical analysis of failure time data. 2nd ed. New York: Wiley; 2002.
20. Kattan MW,Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791 -6.
21. Eilber FC, Brennan MF, Eilber FR, et al.Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 2004;101:2270-5.
22. Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in the management of soft tissue sarcomas. World J Surg 1988;12:326-31.
23. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004;22:4040-50.
24. Takenaka S, Ueda T, Naka N, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 2008;19:467-76.
25. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:4567-74.
26. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65 Suppl 2:80-4.